# OnCo record tg-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/tg-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "tg-therapeutics" ;
  schema:name "TG Therapeutics"@en ;
  schema:alternateName "TG Therapeutics, Inc."@en ;
  schema:description "TG Therapeutics is a New York company whose lymphoma drug umbralisib was approved in 2021 and withdrawn in 2022 over a survival signal, and which now sells the anti-CD20 antibody ublituximab for multiple sclerosis."@en ;
  schema:url <https://onco.cc/companies/tg-therapeutics/>, <https://www.tgtherapeutics.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.tgtherapeutics.com>, <https://clinicaltrials.gov/search?lead=TG%20Therapeutics>, <https://en.wikipedia.org/wiki/TG_Therapeutics> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/pik3cd/> ;
  onco:drugs <https://onco.cc/drugs/umbralisib/> .